You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas
Novartis to acquire Excellergy in USD2bn deal
Login
Username:

Password:


Related Headlines

Novartis to acquire Excellergy in USD2bn deal

Almirall reports lebrikizumab demonstrated sustained long-term control in atopic dermatitis through four years

AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials

Hoth Therapeutics deploys OpenClaw AI platform for drug discovery

Insilico Medicine and Tenacia expand AI-driven R&D collaboration

Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA

Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy

GC Biopharma secures first Latin American approval for BARYCELA Inj.

Iterion Therapeutics reports first patient dosed in phase 1/2 trial of tegavivint in colorectal cancer

SciTech Development reports early-stage clinical data from Phase 1a trial of ST-001 nanoFenretinide at USCLC Annual Workshop 2026

Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics

Merck to acquire Terns Pharmaceuticals for USD6.7bn

Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD

Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026